Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
98 Results for "
Cardiotoxicity
" in MedChemExpress (MCE) Product Catalog:
Products (98)
98 Results for "Cardiotoxicity" in MCE Product Catalog:
Cat. No.: HY-118611
CAS No.: 69635-63-8
Target:
Research Areas:
Amipizone is a cardiotoxic pyridazinone derivative. A variety of pyridazinone compounds are proven to inhibit cardiac type III phosphodiesterase (PDE3). Amipizone is applicable to the research of cardiovascular diseases .
Cat. No.: HY-106172A
CAS No.: 65360-29-4
Target:
Research Areas:
13-Deoxydoxorubicin (GPX-100) hydrochloride is a non-cardiotoxic analogue of Doxorubicin (HY-15142A). 13-Deoxydoxorubicin hydrochloride can be used in the research of soft tissue sarcoma .
Cat. No.: HY-179700
Target:
Research Areas:
COX-2-IN-61 is an orally active COX-2 inhibitor with an IC50 of 22 µM, also inhibits COX-1 with an IC50 of 43 µM. COX-2-IN-61 exhibits anti-inflammation effects in a Carrageenan (HY-125474) induced rat paw edema model, with promising safety profiles. COX-2-IN-61 can be used for the research of inflammation .
Cat. No.: HY-182780
Target:
Research Areas:
LSPN925 is an anticancer agent. LSPN925 exhibits cytotoxic and antiproliferative activities against tumor cells. LSPN925 has predicted oral bioavailability, low risks of hepatotoxicity and acute toxicity, and no risk of cardiotoxicity. LSPN925 can be used for the research of ovarian cancer, melanoma and breast cancer .
Cat. No.: HY-185370
Synonyms: Pegylated liposomal doxorubicin; Liposomal doxorubicin; Doxorubicin hydrochloride liposome
Target:
Research Areas:
Doxorubicin liposome is a liposome-encapsulated form of doxorubicin hydrochloride (HY-15142). Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is a potent human DNA topoisomerase I and topoisomerase II inhibitor. Compared to traditional doxorubicin, liposome encapsulation reduces its cardiotoxicity and prolongs its circulation time, thus enabling it to effectively target tumor tissue.
Cat. No.: HY-K6303
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies.
Cat. No.: HY-109113
CAS No.: 236095-26-4
Synonyms: GPX-150
Target:
Research Areas:
Camsirubicin (GPX-150) is a non-cardiotoxic Doxorubicin (HY-15142) analog that selectively targets topoisomerase IIβ. Camsirubicin reduces cell viability and clone formation of MDA-MB-468 breast cancer cells. Camsirubicin increases the exposure of CALR and HSP90 on the cell surface. Camsirubicin can be used for the study of breast cancer .
Cat. No.: HY-183524
CAS No.: 58893-33-7
Target:
Research Areas:
ICRF 192 is a weak DNA topoisomerase II (DNA topoisomerase II) inhibitor with an IC50 of 91 μM. ICRF 192 forms an iron-chelating derivative via ring-opening hydrolysis, which can displace Fe 3+ from the Fe 3+-doxorubicin complex. ICRF 192 is used for studies on the structure-activity relationship of bisdioxopiperazines and the cardiotoxicity of anthracycline drugs .
Cat. No.: HY-183567
CAS No.: 3030492-72-6
Research Areas:
Ferroptosis-IN-27 is a glutathione peroxidase (GPx) mimetic. Ferroptosis-IN-27 inhibits oxidative stress, reduces intracellular ROS levels, decreases lipid peroxidation and alleviates ferrous ion overload, thereby inhibiting ferroptosis and protecting cardiomyocytes from Doxorubicin (HY-15142A)-induced injury. Ferroptosis-IN-27 can be used in studies related to Doxorubicin-induced cardiotoxicity .
Cat. No.: HY-100489S
Synonyms: tert-Butylhydroquinone-d12
Cat. No.: HY-184939
CAS No.: 3063509-17-8
Research Areas:
THR-β agonist 12 is an orally active, potent, and highly selective thyroid hormone receptor β (THR-β) agonist (EC50 = 36 nM). THR-β agonist 12 shows no significant activity against THRα and exhibits no cardiotoxicity in vivo. THR-β agonist 12 inhibits lipid synthesis by activating the AMPK-ACC-SREBP1 signaling axis. THR-β agonist 12 can be used on research into metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic diseases .
Cat. No.: HY-W012352R
CAS No.: 605-32-3
Cat. No.: HY-W207224
CAS No.: 287177-12-2
Target:
Research Areas:
F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
Cat. No.: HY-10402A
CAS No.: 1246654-84-1
Synonyms: GSK-AHAB hydrochloride; GW856553X hydrochloride; SB856553 hydrochloride
Target:
Research Areas:
Cardiovascular Disease Infection Neurological Disease Cancer
Losmapimod (GSK-AHAB; GW856553X) hydrochloride is an orally active p38α/β MAPK inhibitor, with pKi values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod hydrochloride reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod hydrochloride reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod hydrochloride blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod hydrochloride overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod hydrochloride inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity .
Cat. No.: HY-183476
CAS No.: 36508-71-1
Synonyms: Rubidazon hydrochloride; Rubidazone hydrochloride
Target:
Zorubicin hydrochloride (Rubidazon hydrochloride) is an anthracycline Antibiotic. Zorubicin hydrochloride exhibits activity against breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma. Zorubicin hydrochloride shows activity against undifferentiated nasopharyngeal carcinoma either as a monotherapy or in combination with Cisplatin (HY-17394). Zorubicin hydrochloride can be used in research related to breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma .
Cat. No.: HY-L923
9000 compounds
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.
MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
